Qureight

Qureight is a UK-based, technology-led imaging contract research organisation (CRO) that supplies enterprise-grade imaging services and precision endpoints for clinical trials in lung and heart disease. Its products are delivered through a proprietary data and imaging curation platform that ingests and analyses clinical imaging alongside other healthcare data, covering data curation, quality control, AI image analysis, integration, central reads, clinical trial read-outs and endpoint discovery. Current therapeutic focus areas include interstitial lung diseases (including idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and connective tissue disease-associated ILD), pulmonary hypertension and bronchiectasis.

The company organises its offering into three product lines: global imaging CRO services, including workflow tooling for image handling and infrastructure to onboard trial sites and evaluate participants quickly; AI-powered endpoints and analytics based on deep-learning lung image biomarkers branded Lung8, Air8, Fibr8, Glass8 and Vascul8, used to track treatment response, predict disease progression and characterise baseline disease severity; and data science products built on commercial access to large real-world datasets in IPF, PPF, PH and bronchiectasis, including synthetic control arms and support for early drug development, trial design and toxicity analysis.

Qureight describes itself as an enterprise-grade imaging and AI company working at the intersection of clinical expertise, engineering and machine learning science, with teams spanning machine learning and data science, clinical operations and QARA, platform and engineering, and commercial functions.

Founding story

Qureight was co-founded by Dr Muhunthan Thillai, a board-certified pulmonologist with over 20 years in thoracic medicine who trained at Imperial College London and Oxford, holds a PhD in molecular immunology, and was previously Director of Interstitial Lung Diseases at Royal Papworth and Addenbrooke's Hospitals in Cambridge.

Business model

Qureight sells imaging CRO services, AI-derived imaging endpoints and data science products to biopharmaceutical sponsors running clinical trials in lung and heart disease, delivered through its own imaging and data curation platform.

Revenue comes from biopharma customers contracting Qureight for imaging CRO services, central reads and trial read-outs, AI biomarker endpoints and analytics, and data science products such as synthetic control arms.

Traction

Qureight's services are in use by biopharma partners for trials in fibrotic lung diseases, with customer testimonials from Vicore Pharma (buloxibutid in IPF), Avalyn (MIST study in progressive pulmonary fibrosis) and Rein. The company reported a cross-functional team of 60 people and total disclosed funding of over EUR 27 million after its July 2026 Series B.

Latest developments

In July 2026 Qureight announced a $20 million Series B led by Molten Ventures, with existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension participating. The funding supports an AI imaging laboratory housing its 3D chest imaging Foundation Model, new products in asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity, and expansion of its commercial team. Dr Inga Deakin (Molten Ventures) and Anna Salim (Hargreave Hale) joined the board of directors.